Norwegian Absolute Shortfall severity operationalization (drug reimbursement)
This method helps decide which drugs should be publicly funded in Norway by considering both how cost-effective they are and how severe the disease is. It uses a measure called 'absolute shortfall' to quantify how many quality-adjusted life years a patient group is missing due to their illness, ensuring that treatments for more severe diseases get fairer consideration even if they are more expensive.
At a glance
Use when
Evaluating drug reimbursement proposals where fairness in health distribution is a policy goal; integrating severity of disease into cost-effectiveness analysis; supporting price negotiations in publicly funded health systems
Avoid when
When disease severity cannot be reliably quantified; in systems without centralized pricing or HTA capacity; when only efficiency (not equity) is a decision criterion
Inputs
Disease severity (measured as absolute shortfall in QALYs), incremental cost-effectiveness ratio (ICER), negotiated drug price, baseline health state of the patient population, time horizon of treatment effect
Outputs
Severity-adjusted cost-effectiveness evaluation, recommendation for drug coverage or non-coverage, basis for price negotiation
How it works
The method operationalizes disease severity using the 'absolute shortfall' of quality-adjusted life years (QALYs), defined as the difference between ideal health (1 QALY per year) and the actual health state of the patient population over a defined time horizon. This severity adjustment is integrated into cost-effectiveness analysis by applying severity-differentiated cost-effectiveness thresholds. Drugs for conditions with higher absolute shortfall are evaluated against more lenient thresholds, reflecting societal preferences for equitable health distribution. The approach informs price negotiations and coverage decisions in the Norwegian specialized healthcare system and has been empirically validated using regression analysis of drug appraisal data from 2014–2019.
- HTA domains
- Clinical Effectiveness, Costs & Economic Evaluation, Patient and Social Aspects
- Assumptions
- Health gains have greater value when restoring health in severely ill patients; QALY shortfall can be reliably estimated; societal willingness to pay varies by severity; negotiated prices reflect system affordability
- Strengths
- Integrates equity concerns into economic evaluation in a transparent, systematic way,Empirically validated using real-world reimbursement data,Supports price negotiation by linking severity to acceptable cost-effectiveness thresholds,Applicable across diverse disease areas, especially in oncology
- Limitations
- Dependent on accurate estimation of baseline health states and life expectancy,May favor interventions in chronic severe diseases over acute or less severe conditions,Limited generalizability to systems without centralized price negotiation,Does not account for other equity factors like socioeconomic status or geographic access
- Also known as
- Absolute Shortfall method, Norwegian severity adjustment method, Severity-differentiated cost-effectiveness threshold
Questions this answers
- › How can disease severity be quantified in health technology assessment?
- › How can cost-effectiveness thresholds be adjusted for fairness in resource allocation?
- › How does severity of illness influence drug reimbursement decisions in Norway?
- › How are new, expensive drugs evaluated when they target severe but rare conditions?
- › Can cost-effectiveness analysis incorporate equity concerns systematically?
- › What role does negotiated pricing play in coverage decisions when severity is considered?
References & sources
Similar by meaning
- Norwegian severity classes and severity-weighted cost-effectiveness thresholds (Magnussen approach)
- Swedish severity-based cost-effectiveness threshold framework
- Open and Fair — Norwegian Priority-Setting Criteria (NOU 2014:12, Norheim Committee)
- Proportional Shortfall
- Modifying NICE's Approach to Equity Weighting
Beta record. Generated from the primary source via AI extraction and independent audit, pending final human review.